STOCK TITAN

Electromed - ELMD STOCK NEWS

Welcome to our dedicated page for Electromed news (Ticker: ELMD), a resource for investors and traders seeking the latest updates and insights on Electromed stock.

Overview

Electromed Inc is a Minnesota-based company specializing in the development, manufacturing, and global distribution of innovative medical devices focused on airway clearance therapy. At the heart of its product lineup is the cutting-edge SmartVest Airway Clearance System, which utilizes high frequency chest wall oscillation (HFCWO). This patented technology is designed to deliver effective yet comfortable treatment for patients suffering from conditions that result in compromised pulmonary function.

Core Technology and Product Offerings

The SmartVest system is a hallmark of medical device innovation in pulmonary care. It works by generating programmed air pulses through a specially designed garment, which is worn comfortably over the upper body. This process facilitates vigorous mucus clearance, thereby helping to manage symptoms associated with chronic respiratory conditions such as COPD, cystic fibrosis, bronchiectasis, atelectasis, and neuromuscular disorders.

  • High Frequency Chest Wall Oscillation (HFCWO): A key technological feature that offers an effective alternative to traditional chest physiotherapy.
  • Comfort and Safety: The design ensures that therapy remains well tolerated, promoting compliance among patients.
  • Clinical Validation: The treatment modality has been clinically tested to demonstrate its efficacy in clearing airway secretions and reducing lung infections.

Business Model and Market Position

Electromed generates revenue primarily through the direct sale of its SmartVest system and related products. The company is positioned within the broader healthcare technology and medical devices industry, where stringent regulatory standards and clinical efficacy are paramount. A significant aspect of the company’s market presence involves the continuous commitment to enhancing patient care by using technology that provides a safer and more effective treatment option than conventional methods.

Regulatory and Quality Standards

In the realm of medical devices, adherence to quality and safety protocols is crucial. Electromed maintains a robust certification profile, being accredited by the Joint Commission and certified to standards such as ISO 13485:2003 and ISO 9001:2008. These credentials attest to the company’s adherence to rigorous manufacturing processes and quality management systems, which are essential for ensuring the reliability and safety of its products.

Clinical Impact and Patient Benefits

The clinical utility of the SmartVest system is underscored by its ability to manage and alleviate the symptoms of a variety of pulmonary disorders. Patients benefit from a treatment that is not only effective in clearing airways but also designed to maximize comfort and usability. The system’s evolution reflects innovative responsiveness to clinical needs, contributing to improvements in patient quality of life and overall respiratory health management.

Industry Standing and Competitive Landscape

Within the competitive landscape of airway clearance solutions, Electromed distinguishes itself through its focus on combining technological innovation with stringent quality control. The company’s emphasis on safety, regulatory compliance, and clinical efficacy positions it as a trusted entity among healthcare providers and patients. While the market comprises various devices aiming to improve pulmonary function, Electromed’s strategic focus on HFCWO and its proven clinical benefits set it apart as a specialized and reliable provider.

Expertise and Authoritativeness in Healthcare Technology

Electromed Inc demonstrates a profound commitment to enhancing treatment regimens for respiratory disorders through its advanced medical technologies. Its products are firmly rooted in clinical research and regulatory best practices, making them a reference point for experts in the field. The company’s dedication to meeting high standards of performance and safety underscores its reputation for excellence in healthcare technology.

Summary

The innovative approach adopted by Electromed Inc, particularly through its SmartVest system, reflects its deep-rooted expertise in airway clearance therapy. The company manages to effectively combine state-of-the-art technology with a rigorous quality system to offer a product that improves respiratory care for individuals with complex pulmonary conditions. This comprehensive approach, backed by clinical validation and high regulatory standards, makes Electromed a distinctive presence in the medical device industry.

Rhea-AI Summary

Electromed (NYSE American: ELMD) announced that Summers Value Partners intends to nominate four candidates for election to the Board of Directors at the upcoming Fiscal 2022 Annual Meeting of Shareholders. The Board is currently engaged in discussions with Summers Value Partners to evaluate the nominees, focusing on shareholder interests. With insiders owning over 16% of Electromed's shares, their interests align closely with those of the shareholders. A proxy statement detailing the Board's recommendations will be filed with the SEC and distributed to eligible shareholders.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.38%
Tags
none
-
Rhea-AI Summary

Electromed, Inc. (NYSE American: ELMD) announced preliminary Q4 FY 2021 financial results, projecting net revenue of $9.3 to $9.5 million, a 37% increase from $6.9 million in Q4 FY 2020. Operating income is expected to be between $0.5 and $0.7 million, down from $1.3 million the previous year, which included $0.9 million from government stimulus. The company reported $11.9 million in cash with no debt. Management indicated that a recent data security incident did not materially impact financial results for the quarter, affirming strong performance despite pandemic challenges.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.61%
Tags
-
Rhea-AI Summary

Electromed, a leader in airway clearance technologies (NYSE American: ELMD), announced participation in Canaccord Genuity’s 41st Annual Growth Conference, scheduled for August 10-12, 2021. The group presentation will take place on August 11, 2021, at 10:00 AM Eastern Time. Attendees can access the webcast through a link provided in the press release or via the Investor Relations section of Electromed’s website. The company specializes in airway clearance therapy products, including the SmartVest Airway Clearance System, and was founded in 1992 and is headquartered in New Prague, Minnesota.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.47%
Tags
conferences
Rhea-AI Summary

Electromed, Inc. (NYSE American: ELMD) has announced a $3.0 million stock repurchase authorization effective May 26, 2021. The company plans to buy back its common stock, with purchases made in open market transactions or through block trades. This move is driven by a strong balance sheet and positive cash flow, reflecting management's belief that the stock is undervalued. The buyback program is set to continue until May 26, 2022, but may be modified or discontinued at any time.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.28%
Tags
buyback
-
Rhea-AI Summary

Electromed, Inc. (NYSE American: ELMD) has been recognized as Quality Magazine’s 2021 Plant of the Year. This accolade is based on the 2021 Quality Leadership Top 100 Company survey, which evaluates continuous improvement, quality training, warranty costs, and ISO certifications, including ISO 13485. Electromed has ranked among the top 10 in this survey three times in the last four years. CEO Kathleen Skarvan emphasized the recognition reflects the team's dedication to improving patient lives through high-quality products and services.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.73%
Tags
none
-
Rhea-AI Summary

Electromed, Inc. (NYSE American: ELMD) reported its Q3 FY 2021 financial results, revealing a 0.5% increase in net revenue to $8.8 million, driven by a 4.2% rise in home care revenue. The gross profit percentage improved to 76.3% of net revenue. However, net income fell to $224,000 or $0.03 per diluted share, down from $653,000 or $0.07 in Q3 FY 2020, mainly due to increased investments in R&D and SG&A. Cash at March 31, 2021 stood at $12.5 million, supported by $834,000 in operating cash flow. Despite challenges from COVID-19, management expressed optimism for ongoing recovery.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.86%
Tags
Rhea-AI Summary

Electromed, Inc. (NYSE American: ELMD) is set to release its fiscal 2021 third quarter financial results on May 11, 2021, after market close. The company will host a conference call at 5:00 p.m. Eastern Time to discuss these results. Interested participants can join by calling (877) 407-9753 for domestic calls and (201) 493-6739 for international calls. A live webcast will be accessible via Electromed’s Investor Relations website, and a replay will also be available online post-event.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.2%
Tags
-
Rhea-AI Summary

Electromed, Inc. (NYSE American: ELMD) announced that Kathleen Skarvan, President and CEO, and Mike MacCourt, CFO, will participate in the Sidoti Spring 2021 Virtual Investor Conference on March 24-25, 2021. They will be available for one-on-one meetings during both days. Electromed specializes in airway clearance technology, manufacturing products like the SmartVest® Airway Clearance System, aiding patients with impaired pulmonary function. The group presentation is scheduled for March 24, 2021, at 2:30 PM Eastern Time. Further details can be found on their website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.89%
Tags
conferences
-
Rhea-AI Summary

Electromed (NYSE American: ELMD) reported a 11.1% increase in net revenue, reaching $9.5 million for Q2 FY 2021, driven by a 16.1% rise in home care revenue to $8.9 million. Gross profit margin improved to 79.2%, up from 78.1% in Q2 FY 2020. Net income remained stable at $1.2 million, translating to $0.13 per diluted share. Despite a 37.4% decline in institutional revenue due to COVID-19's impact, the company maintains a robust cash position of $11.7 million. Management expresses cautious optimism for continued growth in the latter half of FY 2021.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.91%
Tags
Rhea-AI Summary

Electromed, Inc. (NYSE American: ELMD) will release its fiscal 2021 second quarter financial results on February 9, 2021, after market close. A conference call will follow at 5:00 p.m. ET to discuss the results. Interested participants can join via phone, with domestic and international numbers provided. The call will also be accessible through a live webcast in the Investor Relations section of Electromed's website. The company manufactures airway clearance products, including the SmartVest Airway Clearance System.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.14%
Tags

FAQ

What is the current stock price of Electromed (ELMD)?

The current stock price of Electromed (ELMD) is $22.39 as of April 4, 2025.

What is the market cap of Electromed (ELMD)?

The market cap of Electromed (ELMD) is approximately 194.8M.

What is the primary focus of Electromed Inc?

Electromed Inc specializes in developing, manufacturing, and marketing medical devices focused on airway clearance therapy, predominantly through its SmartVest system which utilizes high frequency chest wall oscillation (HFCWO).

How does the SmartVest system work?

The SmartVest system employs a programmable air pulse generator connected to a wearable garment, delivering controlled chest wall oscillation that facilitates effective mucus clearance for patients with respiratory conditions.

What conditions can benefit from Electromed's technology?

Patients suffering from conditions such as COPD, cystic fibrosis, bronchiectasis, atelectasis, and various neuromuscular disorders can benefit from the airway clearance therapy provided by the SmartVest system.

Which regulatory standards does Electromed adhere to?

Electromed is accredited by the Joint Commission and holds certifications including ISO 13485:2003 and ISO 9001:2008, ensuring adherence to rigorous quality and safety standards in its manufacturing processes.

How does Electromed differentiate itself from competitors?

The company distinguishes itself through its innovative use of HFCWO technology, a strong commitment to clinical efficacy, and a robust quality management system that ensures patient safety and product reliability.

What is the significance of HFCWO in respiratory care?

High frequency chest wall oscillation (HFCWO) is a critical technology that enhances airway clearance by delivering effective yet comfortable treatment, offering an improved alternative to traditional chest physiotherapy methods.

Who are the primary customers of Electromed's products?

The company primarily serves healthcare providers, clinics, and institutions focused on respiratory care, as well as patients who require effective airway clearance as part of their treatment regimens.

What role do clinical validations play in Electromed's offerings?

Clinical validations ensure that Electromed's products meet strict efficacy and safety benchmarks, reinforcing the company's reputation for reliability and reinforcing trust among healthcare professionals.
Electromed

NYSE:ELMD

ELMD Rankings

ELMD Stock Data

194.75M
6.82M
20.54%
43.56%
2.44%
Medical Devices
Electromedical & Electrotherapeutic Apparatus
Link
United States
NEW PRAGUE